External broker reports(aggregated public sources), Mirae Asset Securities

Mirae Asset Securities

External broker reports(aggregated public sources)

Leading full-service brokerage firm in Vietnam. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>For 2Q25, Seegene posted revenue of W114.1bn (+14% YoY), broadly in line with the consensus.</li><li>HPV (+21% YoY) and gastrointestinal (+31% YoY) test kits saw solid growth, while respiratory (including COVID-19) test kits (-19% YoY) and other products (+8% YoY; -16% YoY for private label products) underperformed.</li><li>Women’s health and extraction reagent revenues rose 1% and 22% YoY, respectively.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

For 2Q25, Seegene posted revenue of W114.1bn (+14% YoY), broadly in line with the consensus.HPV (+21% YoY) and gastrointestinal (+31% YoY) test kits saw solid growth, while respiratory (including COVID-19) test kits (-19% YoY) and other products (+8% YoY; -16% YoY for private label products) underperformed.Women’s health and extraction reagent revenues rose 1% and 22% YoY, respectively.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Seegene (096530 KQ/Buy)Margins Appear to Have Bottomed; 2H Outlook Remains Encouraging

South Korea

Seegene, Inc. manufactures In Vitro Diagnostic (IVD) products mainly through molecular diagnostic method.  The Company provides diagnostic & screening products for cancer, sepsis, influenza and virus infection.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Seegene Inc (096530 KS)

Seegene (096530 KQ/Buy)Margins Appear to Have Bottomed; 2H Outlook Remains Encouraging

For 2Q25, Seegene posted revenue of W114.1bn (+14% YoY), broadly in line with the consensus. HPV (+21% YoY) and gastrointestinal (+31% YoY) test...

Mirae Asset Securities

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)